The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antivirals.
作者信息
Sikorska Katarzyna
机构信息
a Department of Tropical Medicine and Epidemiology , Medical University of Gdańsk , Gdynia , Poland.
b Department of Infectious Diseases , Medical University of Gdańsk , Gdańsk , Poland.
出版信息
Virulence. 2016 Aug 17;7(6):620-2. doi: 10.1080/21505594.2016.1191739. Epub 2016 May 19.
Abstract
摘要
相似文献
1
The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antivirals.
Virulence. 2016 Aug 17;7(6):620-2. doi: 10.1080/21505594.2016.1191739. Epub 2016 May 19.
2
Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):145-147. doi: 10.1016/S2468-1253(18)30004-9. Epub 2018 Jan 19.
3
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
World J Gastroenterol. 2015 Oct 14;21(38):10749-59. doi: 10.3748/wjg.v21.i38.10749.
4
Response to Retreatment of hepatitis C virus Patients in whom Direct-Acting Antivirals have Failed.
Gastroenterol Hepatol. 2019 Nov;42(9):558-561. doi: 10.1016/j.gastrohep.2019.04.002. Epub 2019 Jul 15.
5
Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
Gastroenterology. 2012 May;142(6):1356-9. doi: 10.1053/j.gastro.2011.12.064.
6
Efficacy of Direct-Acting Antivirals in Patients with Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Gap between Clinical Trial and Real Practice.
Gut Liver. 2018 Nov 15;12(6):609-610. doi: 10.5009/gnl18418.
7
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.
8
[A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):165-9. doi: 10.3760/cma.j.issn.1007-3418.2016.03.002.
9
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4.
10
Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
Gastroenterology. 2017 Sep;153(3):867. doi: 10.1053/j.gastro.2017.04.053. Epub 2017 Aug 3.
引用本文的文献
1
Iron as a therapeutic target in chronic liver disease.
World J Gastroenterol. 2023 Jan 28;29(4):616-655. doi: 10.3748/wjg.v29.i4.616.
2
Multi-Omics Sequencing Provides Insights Into Age-Dependent Susceptibility of Grass Carp () to Reovirus.
Front Immunol. 2021 Jun 17;12:694965. doi: 10.3389/fimmu.2021.694965. eCollection 2021.
3
Iron and liver fibrosis: Mechanistic and clinical aspects.
World J Gastroenterol. 2019 Feb 7;25(5):521-538. doi: 10.3748/wjg.v25.i5.521.
4
Differences in responses of grass carp to different types of grass carp reovirus (GCRV) and the mechanism of hemorrhage revealed by transcriptome sequencing.
BMC Genomics. 2017 Jun 8;18(1):452. doi: 10.1186/s12864-017-3824-1.
本文引用的文献
1
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.
Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):338-51. doi: 10.1038/nrgastro.2016.60. Epub 2016 May 5.
2
Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.
Clin Exp Med. 2017 May;17(2):225-232. doi: 10.1007/s10238-016-0423-4. Epub 2016 Apr 28.
3
Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency.
Virulence. 2016 Aug 17;7(6):679-90. doi: 10.1080/21505594.2016.1175700. Epub 2016 Apr 8.
4
Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection.
Hepat Mon. 2014 Nov 1;14(11):e21184. doi: 10.5812/hepatmon.21184. eCollection 2014 Nov.
5
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.
6
Extrahepatic manifestations of chronic hepatitis C virus infection.
Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S165-73. doi: 10.1016/j.dld.2014.10.005. Epub 2014 Nov 8.
7
Virology and cell biology of the hepatitis C virus life cycle: an update.
J Hepatol. 2014 Nov;61(1 Suppl):S3-S13. doi: 10.1016/j.jhep.2014.06.031. Epub 2014 Nov 3.
8
Hepatitis C vaccine. Need of the hour.
Hum Vaccin Immunother. 2014;10(7):1927-9. doi: 10.4161/hv.29033.
9
Global control of hepatitis C: where challenge meets opportunity.
Nat Med. 2013 Jul;19(7):850-8. doi: 10.1038/nm.3184.
10
An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.
J Infect Dis. 2013 Mar;207 Suppl 1(Suppl 1):S1-6. doi: 10.1093/infdis/jis927.
Zotero 插件